Covid-19 roundup: Re­gen­eron scores $2.6B US sup­ply deal for an­ti­body cock­tail; Brazil­ian re­searchers walk back ...

5 years ago
Coronavirus

Bay­er wins pri­or­i­ty re­view for CKD pro­gram finerenone af­ter PhI­II da­ta showed a de­lay in dis­ease pro­gres­sion

5 years ago
FDA+

Flag­ship chris­tens the lat­est start­up to join the drug dis­cov­ery fleet, this time fo­cused on the lessons of cell ...

5 years ago
Startups

Take­da eyes path­way to nat­ur­al killer ther­a­pies, tee­ing up $100M to part­ner with KSQ for its CRISPR-screened ...

5 years ago
Deals
Cell/Gene Tx

Mon­cef Slaoui to step down from Op­er­a­tion Warp Speed in a month — re­port

5 years ago
Coronavirus

Am­gen ponies up $240M for Michi­gan dis­cov­ery out­fit's den­drit­ic cell tar­get­ing mol­e­cules for au­toim­mune dis­or­ders

5 years ago
Deals

With KRAS break­through on the hori­zon, Am­gen's David Reese re­flects on so­tora­si­b's loom­ing re­view date and murky ...

5 years ago
People
R&D

Spark co-founder Kathy High joins a long­time col­lab­o­ra­tor at AskBio, help­ing steer Bay­er's gene ther­a­py push

5 years ago
People
Cell/Gene Tx

News brief­ing: Ab­b­Vie se­lects first tar­get for Drag­on­fly part­ner­ship; Cog­ni­to nets BDD for Alzheimer's treat­ment ...

5 years ago
News Briefing

Mer­ck snags pri­or­i­ty re­view for Pre­vnar 13 ri­val — just one month af­ter Pfiz­er sent its fol­low-on to the FDA

5 years ago
FDA+

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

5 years ago
Pharma

Abzena plots 6th bi­o­log­ics plant as de­mand for mam­malian cell-line pro­duc­tion con­tin­ues to grow

5 years ago
Manufacturing

Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for com­bi­na­tion tri­al

5 years ago
R&D

Covid-19 roundup: Trump ad­min­is­tra­tion plan­ning to speed up shots; EMA to re­view As­traZeneca/Ox­ford vac­cine

5 years ago
Coronavirus

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

5 years ago
Deals
AI

Once aim­ing to dou­ble on­col­o­gy pipeline, Servier's US branch touts rapid pace in build­ing its foothold in the space

5 years ago
Manufacturing

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

5 years ago
Deals

With a tor­rent of ven­ture cash gush­ing from a glob­al pack of uni­corn hunters, this biotech founder vows to stay ...

5 years ago
Financing

Trump's HHS con­tin­ues to as­sert au­thor­i­ty over FDA in twi­light of his pres­i­den­cy, im­ple­ment­ing new drug time­line ...

5 years ago
Pharma
FDA+

Look­ing to leapfrog an­ti­bod­ies and RNAi, Sekar Kathire­san says gene edit­ing ap­proach to cut PC­SK9 looks durable

5 years ago
R&D
Discovery

Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

5 years ago
Deals

Next-gen ther­a­pies are evolv­ing fast. The drug de­vel­op­ment mod­el needs to keep up

5 years ago
Biotech Voices

Af­ter pan­dem­ic-re­lat­ed dis­rup­tions, will 2021 bring about a re­newed spot­light on R&D? A CFO sur­vey says yes

5 years ago
Pharma

No­var­tis brings BeiGene's promis­ing check­point in­hibitor in­to the fold, but what about high­ly tout­ed spar­tal­izum­ab?

5 years ago
Deals
First page Previous page 748749750751752753754 Next page Last page
A service from the Financial Times